Vínculo: A Digital Intervention for Anxiety, Depression, and Insomnia Symptoms (VINCULO-ADI)
Vínculo: A Randomized Controlled Trial of a Guided Digital Intervention for Anxiety, Depression, and Insomnia Symptoms
Insomnia, anxiety, and depression are common mental health problems that frequently occur together. Psychological interventions that address shared processes underlying these symptoms may offer an accessible way to improve mental health and sleep.
This study will evaluate the effectiveness of Vínculo, an eight-week, guided digital psychological intervention for adults experiencing clinically significant symptoms of insomnia, anxiety, and/or depression.
Approximately 305 adults living in Brazil will be randomly assigned to one of two groups. The experimental group will receive Vínculo, a psychological intervention delivered through a WhatsApp chatbot that combines acceptance and commitment therapy, behavioral activation, and behavioral strategies for sleep. The comparison group will receive an eight-week digital psychoeducation program covering mental health, emotions, sleep, and healthy lifestyle habits.
Both groups will receive structured content through WhatsApp, three individual videoconference sessions with a psychologist, and access to asynchronous psychological support during the intervention.
The main objective is to determine whether Vínculo is more effective than digital psychoeducation in reducing insomnia severity, depressive symptoms, and anxiety symptoms after eight weeks. Participants will also be assessed three and six months after the intervention to examine whether improvements are maintained. Additional assessments will examine daily functioning and psychological processes related to treatment outcomes.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This study is a fully remote, open-label, two-arm, parallel-group randomized controlled trial designed to evaluate the efficacy of Vínculo, a guided digital transdiagnostic psychological intervention, compared with an active digital psychoeducation control condition.
The study will enroll approximately 305 adults aged 18-59 years living in Brazil who report clinically significant symptoms in at least one of three domains: insomnia, depression, or anxiety. Eligibility will be established through electronic screening followed by a structured clinical assessment. A formal psychiatric diagnosis will not be required for inclusion.
After baseline assessment, participants will be randomized in a 1:1 ratio using computer-generated, randomly permuted blocks of varying sizes. Randomization will be stratified according to eight possible baseline symptom profiles, defined by the presence or absence of clinically significant insomnia, depression, and anxiety symptoms. Allocation will be implemented through REDCap.
The experimental intervention is based on process-based therapy and integrates components of acceptance and commitment therapy, behavioral activation, and behavioral strategies for insomnia. Therapeutic content will address emotional awareness, experiential avoidance, mindfulness, values clarification, committed action, behavioral activation, acceptance, cognitive defusion, sleep-related behaviors, and relapse prevention. Behavioral sleep strategies will be introduced in Week 4 and will not include sleep restriction.
The active control condition will provide structured psychoeducation about mental health, emotional symptoms, sleep, and healthy lifestyle habits without introducing the specific therapeutic techniques of the experimental intervention.
Both conditions will last eight weeks. Structured digital content will be delivered through WhatsApp three times weekly, with reminders on alternate days. Participants in both groups will receive three individual videoconference sessions with a psychologist and access to asynchronous professional support on business days. The content of professional support will be specific to each assigned condition.
The three co-primary outcomes are insomnia severity, depressive symptoms, and anxiety symptoms, assessed one week after completion of the eight-week intervention using the Insomnia Severity Index (ISI), Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder-7 (GAD-7), respectively.
Secondary assessments will examine symptom severity at three- and six-month follow-ups, functional impairment, clinical response, behavioral activation, and psychological flexibility. Exploratory assessments will address anhedonia and working alliance.
The primary analyses will compare treatment groups while accounting for baseline symptom severity. The study will also investigate treatment effects across different baseline symptom presentations and evaluate changes in psychological processes associated with clinical outcomes.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Renatha El Rafihi-Ferreira, PhD
- Phone Number: +5511991841188
- Email: protocolovinculo@gmail.com
Study Locations
-
-
São Paulo
-
São Paulo, São Paulo, Brazil, 05508-030
- Institute of Psychology, University of São Paulo
-
Contact:
- Renatha El Rafihi-Ferreira, PhD
- Phone Number: +5511991841188
- Email: protocolovinculo@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults aged 18 to 59 years.
- Clinically significant symptoms in at least one of the following domains at screening:
- Insomnia: Insomnia Severity Index (ISI) score ≥11;
- Depression: Patient Health Questionnaire-9 (PHQ-9) score ≥10;
- Anxiety: Generalized Anxiety Disorder-7 (GAD-7) score ≥10.
- Residence in Brazil.
- Ability to read and understand written Portuguese.
- Regular access to WhatsApp on a personal device.
- Willingness and availability to participate in the intervention and complete the scheduled study assessments.
- Provision of electronic informed consent.
Exclusion Criteria:
- Current diagnosis of bipolar disorder or psychotic disorder, or severe suicide risk.
- Substance use disorder that would substantially interfere with participation in the intervention or completion of study assessments.
- Severe and unstable neurological or medical conditions, such as dementia or advanced-stage cancer.
- Night-shift work that cannot be reorganized.
- Significant cognitive impairment that would hinder participation in the digital intervention.
- Unavailability to participate in the intervention or complete the scheduled study assessments.
- Use of sleep medication, either regularly or intermittently, without a stable medication use pattern for at least 2 months before enrollment, including recent initiation or substantial changes in the regimen.
- Use of antidepressants or other psychotropic medications intended for regular use without a stable regimen for at least 1 month following a dose adjustment or 2 months following initiation of a new medication.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Vínculo Digital Intervention
Participants will receive Vínculo, an eight-week guided digital transdiagnostic psychological intervention delivered through a WhatsApp chatbot. The intervention integrates acceptance and commitment therapy, behavioral activation, and behavioral sleep strategies. Structured content will be delivered on Mondays, Wednesdays, and Fridays, with reminders on Tuesdays, Thursdays, and Saturdays. Participants will also receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous psychological support on business days (Monday to Friday). |
Vínculo is an eight-week guided digital transdiagnostic psychological intervention delivered through a WhatsApp chatbot. Based on process-based therapy, it integrates acceptance and commitment therapy, behavioral activation, and behavioral sleep regulation. Components include mindfulness, acceptance, cognitive defusion, values clarification, committed action, and behavioral activation. Sleep-related content is addressed throughout the intervention, including psychoeducation, stimulus control, a consistent wake time, daytime activity, morning natural light exposure, and a wind-down routine. Content is delivered three times weekly, with reminders on alternate days. Participants receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous psychological support on business days. |
|
Active Comparator: Digital Psychoeducation
Participants will receive an eight-week digital psychoeducation program delivered through a WhatsApp chatbot. The program provides information about mental health, emotional symptoms, sleep, and healthy lifestyle habits, without introducing the specific therapeutic techniques used in the experimental intervention. Structured content will be delivered on Mondays, Wednesdays, and Fridays, with reminders on Tuesdays, Thursdays, and Saturdays. Participants will also receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous professional support on business days (Monday to Friday), limited to clarifying psychoeducational content, addressing technical difficulties, and supporting engagement. |
An eight-week digital psychoeducation program delivered through a WhatsApp chatbot. The program provides structured information about mental health, emotional symptoms, sleep, and healthy lifestyle habits, without introducing the specific therapeutic techniques of the experimental intervention. Content is delivered three times weekly, with reminders on alternate days. Participants receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous professional support on business days. Professional support is limited to clarifying psychoeducational content, addressing technical difficulties, and supporting engagement. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Insomnia Symptom Severity (Insomnia Severity Index - ISI)
Time Frame: One week after completion of the 8-week intervention
|
The Insomnia Severity Index (ISI) is a seven-item self-report questionnaire assessing insomnia symptom severity. Total scores range from 0 to 28, with higher scores indicating greater insomnia severity. The primary outcome is the ISI total score at post-treatment, adjusted for baseline severity. |
One week after completion of the 8-week intervention
|
|
Depressive Symptom Severity (Patient Health Questionnaire-9 - PHQ-9)
Time Frame: One week after completion of the 8-week intervention
|
The Patient Health Questionnaire-9 (PHQ-9) is a nine-item self-report questionnaire assessing depressive symptom severity. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. The primary outcome is the PHQ-9 total score at post-treatment, adjusted for baseline severity. |
One week after completion of the 8-week intervention
|
|
Anxiety Symptom Severity (Generalized Anxiety Disorder-7 - GAD-7)
Time Frame: One week after completion of the 8-week intervention
|
The Generalized Anxiety Disorder-7 (GAD-7) is a seven-item self-report questionnaire assessing anxiety symptom severity. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity. The primary outcome is the GAD-7 total score at post-treatment, adjusted for baseline severity. |
One week after completion of the 8-week intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Insomnia Symptom Severity at Follow-up (Insomnia Severity Index - ISI)
Time Frame: 3 and 6 months after completion of the 8-week intervention
|
The Insomnia Severity Index (ISI) is a seven-item self-report questionnaire assessing insomnia symptom severity. Total scores range from 0 to 28, with higher scores indicating greater insomnia severity. ISI total scores will be assessed at the 3-month and 6-month follow-ups to evaluate maintenance of treatment effects, adjusting for baseline severity. |
3 and 6 months after completion of the 8-week intervention
|
|
Depressive Symptom Severity at Follow-up (Patient Health Questionnaire-9 - PHQ-9)
Time Frame: 3 and 6 months after completion of the 8-week intervention
|
The Patient Health Questionnaire-9 (PHQ-9) is a nine-item self-report questionnaire assessing depressive symptom severity. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. PHQ-9 total scores will be assessed at the 3-month and 6-month follow-ups to evaluate maintenance of treatment effects, adjusting for baseline severity. |
3 and 6 months after completion of the 8-week intervention
|
|
Anxiety Symptom Severity at Follow-up (Generalized Anxiety Disorder-7 - GAD-7)
Time Frame: 3 and 6 months after completion of the 8-week intervention
|
The Generalized Anxiety Disorder-7 (GAD-7) is a seven-item self-report questionnaire assessing anxiety symptom severity. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity. GAD-7 total scores will be assessed at the 3-month and 6-month follow-ups to evaluate maintenance of treatment effects, adjusting for baseline severity. |
3 and 6 months after completion of the 8-week intervention
|
|
Functional Impairment (Sheehan Disability Scale - SDS)
Time Frame: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
The Sheehan Disability Scale (SDS) is a three-item self-report measure assessing functional impairment in work or school, social life, and family life or home responsibilities. Each domain is scored from 0 to 10, with a total score ranging from 0 to 30. Higher scores indicate greater functional impairment. |
One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
|
Behavioral Activation (Behavioral Activation for Depression Scale - Short Form, BADS-SF)
Time Frame: Week 4, one week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
The Behavioral Activation for Depression Scale - Short Form (BADS-SF) is a nine-item self-report measure assessing behavioral activation and avoidance. Total scores range from 0 to 54, with higher scores indicating greater behavioral activation. Changes in behavioral activation will be evaluated across the scheduled assessments. |
Week 4, one week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
|
Psychological Flexibility (Comprehensive Assessment of Acceptance and Commitment Therapy Processes - CompACT)
Time Frame: Week 4, one week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
The Comprehensive Assessment of Acceptance and Commitment Therapy Processes (CompACT) is a 23-item self-report measure assessing psychological flexibility through openness to experience, behavioral awareness, and valued action. Total scores range from 0 to 138, with higher scores indicating greater psychological flexibility. |
Week 4, one week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
|
Clinical Response in Insomnia Symptoms (ISI)
Time Frame: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
Clinical response in insomnia symptoms will be defined as a reduction of at least 8 points in the Insomnia Severity Index (ISI) total score relative to baseline. The outcome will be expressed as the proportion of participants meeting this predefined response criterion at each assessment. |
One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
|
Clinical Response in Depressive Symptoms (PHQ-9)
Time Frame: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
Clinical response in depressive symptoms will be defined as a reduction of at least 50% in the Patient Health Questionnaire-9 (PHQ-9) total score relative to baseline. The outcome will be expressed as the proportion of participants meeting this predefined response criterion at each assessment. |
One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
|
Clinical Response in Anxiety Symptoms (GAD-7)
Time Frame: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
Clinical response in anxiety symptoms will be defined as a reduction of at least 50% in the Generalized Anxiety Disorder-7 (GAD-7) total score relative to baseline. The outcome will be expressed as the proportion of participants meeting this predefined response criterion at each assessment. |
One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anhedonia (Snaith-Hamilton Pleasure Scale - SHAPS)
Time Frame: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
The Snaith-Hamilton Pleasure Scale (SHAPS) is a 14-item self-report questionnaire assessing anhedonia, defined as a reduced capacity to experience pleasure. Using conventional dichotomous scoring, total scores range from 0 to 14, with higher scores indicating greater anhedonia. Changes in anhedonia will be evaluated as an exploratory outcome. |
One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
|
|
Therapeutic Alliance (Working Alliance Inventory for Guided Internet Interventions - WAI-I)
Time Frame: Week 4 and one week after completion of the 8-week intervention
|
The Working Alliance Inventory for Guided Internet Interventions (WAI-I) is a self-report measure assessing the therapeutic alliance in guided internet-based psychological interventions, including agreement on therapeutic goals, agreement on tasks, and the therapeutic bond. Higher scores indicate a stronger therapeutic alliance. Therapeutic alliance will be evaluated as an exploratory outcome. |
Week 4 and one week after completion of the 8-week intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Renatha El Rafihi-Ferreira, PhD, University of Sao Paulo
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CISM-VINCULO-ADI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data sharing has not yet been determined. Study data will be securely stored, and access will be restricted to authorized research personnel in accordance with institutional policies, ethical approvals, and Brazilian data protection legislation. The possibility of sharing de-identified participant data for scientific purposes will be evaluated in accordance with applicable ethical and institutional requirements.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.